161 related articles for article (PubMed ID: 37554164)
1. Diagnostic accuracy of
Li B; Duan L; Li X; Shi J; Li H; Liu H; Cheng X; Wu X; Gao Y
Front Oncol; 2023; 13():1228575. PubMed ID: 37554164
[TBL] [Abstract][Full Text] [Related]
2. Effective detection of the tumors causing osteomalacia using [Tc-99m]-HYNIC-octreotide (99mTc-HYNIC-TOC) whole body scan.
Jing H; Li F; Zhuang H; Wang Z; Tian J; Xing X; Jin J; Zhong D; Zhang J
Eur J Radiol; 2013 Nov; 82(11):2028-34. PubMed ID: 23721625
[TBL] [Abstract][Full Text] [Related]
3. 99mTc-HYNIC-TOC in the Evaluation of Recurrent Tumor-Induced Osteomalacia.
Shi X; Jing H; Li F; Zhao Y; Wang Z; Huo L
Clin Nucl Med; 2019 Mar; 44(3):209-213. PubMed ID: 30672760
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic performance and impact on patient management of
Paquet M; Gauthé M; Zhang Yin J; Nataf V; Bélissant O; Orcel P; Roux C; Talbot JN; Montravers F
Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1710-1720. PubMed ID: 29532101
[TBL] [Abstract][Full Text] [Related]
5. [Value of
Zhang S; Wang L; Wang T; Xing HQ; Huo L; Li F
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2018 Dec; 40(6):757-764. PubMed ID: 30606385
[TBL] [Abstract][Full Text] [Related]
6. Clinical value of
Chen H; Li Y; Gao X; Shen X
Clin Imaging; 2018; 52():365-369. PubMed ID: 30248495
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of indigenously formulated single-vial lyophilized HYNIC-TOC kit in evaluating Gastro-entero Pancreatic neuro endocrine tumours.
Shinto AS; Kamaleshwaran K; Vyshak K; Sudhakar N; Banerjee S; Korde A; Samuel G; Mallia M
Asia Ocean J Nucl Med Biol; 2014; 2(1):30-41. PubMed ID: 27408857
[TBL] [Abstract][Full Text] [Related]
8. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors.
Gabriel M; Decristoforo C; Donnemiller E; Ulmer H; Watfah Rychlinski C; Mather SJ; Moncayo R
J Nucl Med; 2003 May; 44(5):708-16. PubMed ID: 12732671
[TBL] [Abstract][Full Text] [Related]
9. Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT.
Madrzak D; Mikołajczak R; Kamiński G
Nucl Med Rev Cent East Eur; 2016; 19(2):88-92. PubMed ID: 27479886
[TBL] [Abstract][Full Text] [Related]
10. 99mTc-HYNIC-TOC scintigraphy is superior to 131I-MIBG imaging in the evaluation of extraadrenal pheochromocytoma.
Chen L; Li F; Zhuang H; Jing H; Du Y; Zeng Z
J Nucl Med; 2009 Mar; 50(3):397-400. PubMed ID: 19223405
[TBL] [Abstract][Full Text] [Related]
11. Incremental value of
Trogrlic M; Težak S
Nuklearmedizin; 2017 Jun; 56(3):97-107. PubMed ID: 28164207
[TBL] [Abstract][Full Text] [Related]
12. 99mTc-EDDA/HYNIC-TOC in management of patients with head and neck somatostatin receptor positive tumors.
Trogrlic M; Tezak S
Nucl Med Rev Cent East Eur; 2016; 19(2):74-80. PubMed ID: 27479884
[TBL] [Abstract][Full Text] [Related]
13. Clinical indications to the use of (99m)Tc-EDDA/HYNIC-TOC to detect somatostatin receptor-positive neuroendocrine tumors.
Parisella MG; Chianelli M; D'Alessandria C; Todino V; Mikolajczak R; Papini E; Dierckx RA; Scopinaro F; Signore A
Q J Nucl Med Mol Imaging; 2012 Feb; 56(1):90-8. PubMed ID: 21068709
[TBL] [Abstract][Full Text] [Related]
14. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.
Gabriel M; Decristoforo C; Kendler D; Dobrozemsky G; Heute D; Uprimny C; Kovacs P; Von Guggenberg E; Bale R; Virgolini IJ
J Nucl Med; 2007 Apr; 48(4):508-18. PubMed ID: 17401086
[TBL] [Abstract][Full Text] [Related]
15. Clinical application of
Xu J; Li Y; Xu X; Zhang J; Zhang Y; Yu X; Huang D
Ann Nucl Med; 2018 Aug; 32(7):446-452. PubMed ID: 29926342
[TBL] [Abstract][Full Text] [Related]
16. 99mTc-HYNIC-TOC (99mTc-hydrazinonicotinyl-Tyr3-octreotide) scintigraphy identifying two separate causative tumors in a patient with tumor-induced osteomalacia (TIO).
Jing H; Li F; Zhong D; Zhuang H
Clin Nucl Med; 2013 Aug; 38(8):664-7. PubMed ID: 23797229
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic value of 68Ga-DOTA-TATE PET/CT imaging for tumor- induced osteomalacia.
Zhang Y; Zhang X; Zhang W; Huang Z; Chen Y
Ann Palliat Med; 2020 Sep; 9(5):3350-3356. PubMed ID: 32921125
[TBL] [Abstract][Full Text] [Related]
18.
Liepe K; Becker A
World J Nucl Med; 2018; 17(3):151-156. PubMed ID: 30034278
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma.
Czepczyński R; Parisella MG; Kosowicz J; Mikołajczak R; Ziemnicka K; Gryczyńska M; Sowiński J; Signore A
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1635-45. PubMed ID: 17530247
[TBL] [Abstract][Full Text] [Related]
20. 68Ga DOTA-TATE PET/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT/CT.
Breer S; Brunkhorst T; Beil FT; Peldschus K; Heiland M; Klutmann S; Barvencik F; Zustin J; Gratz KF; Amling M
Bone; 2014 Jul; 64():222-7. PubMed ID: 24769333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]